WASHINGTON, Nov 28 (Reuters) - A Pfizer Inc. trial of pain reliever Celebrex has design limitations that raise questions about the drug’s effectiveness for treating juvenile rheumatoid arthritis, U.S. Food and Drug Administration staff said in an analysis released on Tuesday.
